Dishman Carbogen Amcis Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/u8uatty9a4xqr7aiwbvjv43p.pdf

Key Takeaways


The Quarter: What Happened and Why

Dalal: "The right way to look at our business would be more on a yearly basis, if not on a two-yearly basis."

CDMO: The Core Engine

Dalal: "Our people, they are extremely talented, the scientists that we have, and that is the reason we have been able to crack this kind of complex technologies, which people are talking about today, which we had mastered 15 years back."

India: The Margin Recovery Bet

Dalal: "This is the site which is going to give us the highest margins as far as the entire group is concerned."

Marketable Molecules: The Quiet Improver

Dalal: "As you look into the future for this particular segment, and more specifically cholesterol and vitamin D analogs, we would keep on seeing the margin improvements, where our target is to first get to the 20% margin and then take it up to 25%."

Capacity, Sites, and the Global Footprint

SiteUtilizationCommentary
Switzerland75%Capacity-constrained on large-volume work; focus is niche, oncology, ADC/HPAPI.
France20%Just started last year; delayed truck substance supply pushed revenue into FY27; expected breakeven at EBITDA level in FY27 with both lines running, revenue near EUR 1.8 crore.
Netherlands60%Wool grease sourcing improvements underway for cholesterol production.
Manchester75%No specific constraints flagged.
Shanghai50%Received local FDA certification; new salesperson hired; target to reach ~75% utilization.
India (Bavla)20-25%Highest-margin site in the group; target 2.5x utilization increase in three years.

Balance Sheet & Capital Allocation

Dalal: "Ideally speaking, we would want to make the India debt zero."

Guidance & Commitments

CommitmentSpecificsTimeline
Q4 revenue recoveryRevenue higher by the delayed ~INR 20 crores than previously expectedQ4 FY26
Full-year FY26 growthGrowth rate "much higher" than the 4.3% reported for 9M, more or less in line with prior guidanceFY26 exit
Full-year FY26 EBITDA margin19.5% to 20% (target still stands)FY26 exit
India revenueINR 500 crores12-18 months
India revenueINR 800 crores3-5 years
India utilization2.5x current production capacity utilization3 years
Consolidated EBITDA margin25-26% (pre-March 2020 level)2 years
Consolidated EBITDA margin30%By end of 2030
Marketable Molecules margin20%, then 25%No date (target stated)
French subsidiaryEBITDA breakeven with both manufacturing linesFY27
French subsidiary revenue~EUR 1.8 croreFY27
Shanghai utilization~75% (from current 50%)No date (target stated)
Swiss development revenueDouble from current level5 years
ADC capacity expansion (second co-investment)Completed~1.5 years
India debtZero3 years
Japanese customer visibilityFair revenue visibility from existing co-investmentAt least 3 years

Key Metrics

MetricQ3 FY26
Revenue₹720 cr, +5.5% YoY; expected ₹20 cr higher but delayed shipment pushed to January
EBITDA₹113 cr, margin of 15.7%
EBITDA margin (9M FY26)19.4%, vs 15.9% in 9M FY25; full-year FY26 target of 19.5%–20%
Profit after taxNegative ₹12.97 cr
Profit before tax (9M FY26)₹58.76 cr
Profit after tax (9M FY26)₹75.7 cr, after accounting for deferred tax asset largely from the French facility
COGS~20% of revenue, vs ~15% in Q3 FY25, driven by higher commercial supply mix
Employee expenses₹355 cr, vs ₹332 cr in Q3 FY25; includes severance and social insurance provisions
Finance cost₹45.7 cr, including a one-time expense of ~₹11 cr from refinancing and credit facility enhancement in Switzerland
CDMO segment revenue₹630 cr, +6.7% YoY; 9M FY26 at ₹1,750 cr vs ₹1,723 cr in 9M FY25
CDMO segment EBITDA margin~17%, vs 22% in Q3 FY25; 9M FY26 at 19.7% vs 17.2%, up ~250 bps
Marketable Molecules segment revenue₹90 cr, flattish YoY; 9M FY26 at ₹330 cr, +21.5% YoY
Marketable Molecules segment EBITDA margin7.2%; 9M FY26 at 17.5% vs 8.3%, up 920 bps
India (Bavla) site revenue (9M FY26)~₹150 cr; FY26 guidance of ₹250–₹290 cr
India site RFP pipeline₹1,200 cr worth of RFPs given out; 30%–35% expected conversion
India site revenue target₹500 cr in next 12–18 months, then ₹800 cr in 3–5 years
French subsidiary revenue (9M FY26)€7 mn; full-year FY26 expected at €9.5–€10 mn; FY27 target ~€1.8 cr (likely €18 mn based on context)
Swiss site capacity utilization~75%
India site capacity utilization~20%–25%
French site capacity utilization~20%
Net debt~CHF 15 crore
India debt~₹750 cr; target to reduce to zero over next 3 years via operational cash flows
ADC linker-payload supply (FY25)CHF 2.2 cr; FY26 expected ~CHF 3 cr; FY27 expected ~CHF 4 cr
Second co-investment with Japanese customerCHF 2.5 cr, expected to contribute ~CHF 3 cr of incremental revenue